Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion Healthcare Gears Up For Infliximab SC Launch

UK Commercial Head Reveals Strategy For Innovative Biosimilar Infliximab

Executive Summary

As Celltrion Healthcare prepares to roll out Remsima SC, its subcutaneous infliximab, in Europe – starting in the UK and Germany – Celltrion Healthcare’s UK commercial head, Matthew Eddleston, speaks to Generics Bulletin about how the innovative biosimilar will be positioned in the market.

You may also be interested in...



Celltrion Says New Data Prove Remsima SC Is A ‘Biobetter’

Celltrion says new data show that its Remsima SC subcutaneous infliximab biosimilar produces “statistically greater improvements in clinical outcomes” for rheumatoid arthritis patients compared to intravenous infliximab.

Celltrion Launches Remsima SC In UK

Celltrion has launched Remsima SC in the UK. Meanwhile, the innovative subcutaneous version of biosimilar infliximab has also received approval in Korea.

Celltrion Sets Out Strategy For China

Celltrion has unveiled plans to construct a biologics plant in Wuhan, China, as well as setting up a direct sales network in the country, as part of its wider global strategy that also involves launching a new biosimilar every year to 2030.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149651

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel